CELUW Live signals | Maximize Profits with Getagraph.com

Live Chart Being Loaded With Signals

Commentary (20 May 2024 @ 12:09):

Celularity Inc., a clinical-stage biotechnology company, develops off-the-shelf placental-derived allogeneic cell therapies for the treatment of cancer, immune, and infectious diseases...

Stats
Today's Volume	28 196.00
Average Volume	0.00
Market Cap	104.56M
EPS	$-0.000270 ( 2023-06-29 )
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.0300
ATR14	$0 (0.00%)

Insider Trading

Date	Person	Action	Amount	type
2024-01-12	Lim Kok Thay	Buy	21 410 983	Class A Common Stock
2024-01-12	Lim Kok Thay	Buy	16 500 000	Warrants (Right to Buy)
2024-01-12	Lim Kok Thay	Buy	6 529 818	Warrants (Right to Buy)
2024-01-12	Lim Kok Thay	Buy	5 352 746	Warrants (Right to Buy)
2024-01-12	Lim Kok Thay	Sell	6 529 818	Warrants (Right to Buy)

INSIDER POWER
55.67
Last 92 transactions
Buy: 110 408 052 \| Sell: 53 673 583

Celularity Inc. Correlation

10 Most Positive Correlations

10 Most Negative Correlations

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Celularity Inc. Financials

Annual	2022
Revenue:	$17.98M
Gross Profit:	$-1.69M (-9.40 %)
EPS:	$1.010

FY	2022
Revenue:	$17.98M
Gross Profit:	$-1.69M (-9.40 %)
EPS:	$1.010

FY	2021
Revenue:	$21.34M
Gross Profit:	$11.68M (54.76 %)
EPS:	$-0.00100

FY	2020
Revenue:	$14.28M
Gross Profit:	$9.35M (65.46 %)
EPS:	$-0.0000335

Financial Reports:

No articles found.

Celularity Inc. Options Data

Calls

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Puts

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Celularity Inc.

Celularity Inc., a clinical-stage biotechnology company, develops off-the-shelf placental-derived allogeneic cell therapies for the treatment of cancer, immune, and infectious diseases. It operates through three segments: Cell Therapy, Degenerative Disease, and BioBanking. The company's lead therapeutic programs include CYCART-19, a placental-derived CAR-T therapy, which is in Phase I clinical trial for the treatment of B-cell malignancies; CYNK-001, placental-derived unmodified natural killer (NK) cell that is in Phase I clinical trial to treat acute myeloid leukemia, as well as in Phase I/IIa clinical trial for the treatment of glioblastoma multiforme and COVID-19; CYNK-101, an allogeneic genetically modified NK cell, which is in Phase I clinical trial to treat HER2+ gastric and gastroesophageal cancers; APPL-001, a placenta-derived mesenchymal-like adherent stromal cell that is in a pre-clinical stage for the treatment of Crohn's disease; and PDA-002, a placenta-derived mesenchymal-like adherent stromal cell, which is in pre-clinical stage for the treatment of facioscapulohumeral muscular dystrophy. It also sells and licenses products that are used in surgical and wound care markets, such as Biovance and Interfyl; collects stem cells from umbilical cords and placentas; and provides cells storage under the LifebankUSA brand. The company was incorporated in 2016 and is headquartered in Florham Park, New Jersey.